



# Seale & Associates

CLINICAL LABORATORY SERVICES INDUSTRY  
VALUATION UPDATE  
Q2 2026

# Table of Contents

|                   |   |
|-------------------|---|
| Industry Overview | 4 |
|-------------------|---|

|                                    |   |
|------------------------------------|---|
| Global Comparable Public Companies | 5 |
|------------------------------------|---|

|                     |   |
|---------------------|---|
| Global Transactions | 7 |
|---------------------|---|

|             |   |
|-------------|---|
| About Seale | 8 |
|-------------|---|




# Introduction

We are pleased to share our Clinical Laboratory Services Industry Valuation Multiples Update for Q2 2026.

At Seale & Associates, we are committed to providing process-driven solutions designed to optimize value and achieve our client’s strategic objectives in a range of transactions, including **Mergers, Acquisitions, Divestitures and Carve-Outs, Business Sales, Recapitalizations, and Joint Ventures**, among other corporate finance and strategy consulting services.

Over the course of 25+ years, we have successfully served clients all over the world, and we are delighted to continue providing investment banking advisory services to our clients who are looking to grow through acquisitions or optimize their portfolios through strategic divestitures.

Seale has extensive experience advising leading multinational companies, private equity firms, and family-owned businesses across a wide range of industries.



**James A. Seale | President**  
jseale@sealeassociates.com



**Brett M. Carmel | Senior Managing Director**  
bcarmel@sealeassociates.com




**Robert Whitney | Managing Director**  
rwhitney@sealeassociates.com



**Sergio Garcia del Bosque | Managing Director**  
sgarcia@sealeassociates.com



**Carlos Hernandez Goudet | Managing Director**  
chernandez@sealeassociates.com



**Alejandro Montemayor | Director**  
amontemayor@sealeassociates.com




**Armando Rios | Vice President**  
arios@sealeassociates.com

# Clinical Laboratory Services Industry Overview


## M&A Trends and Market Intelligence

- The **global clinical laboratory services market** revenue was valued at **US\$291.0B in 2025** and is projected to reach **US\$545.7B by 2034**, growing at a **CAGR of 7.4%** during the forecast period. The industry continues to benefit from **increasing demand for diagnostic testing services**, with **North America** representing the **largest regional market**
- Market growth continues to be driven** by the **rising prevalence of chronic diseases, aging populations, increasing healthcare expenditures, and growing awareness** surrounding preventive healthcare and early disease diagnosis
- Growing adoption of **automated laboratory systems, AI-powered diagnostics, genetic testing, and advanced data analytics** is improving testing efficiency, accuracy, and scalability **across clinical laboratories globally**
- Increasing investments in laboratory automation, advanced diagnostic technologies, and strategic partnerships** among healthcare providers and laboratory operators continue to support **long-term industry growth** across **hospital-based, stand alone, and clinic-based laboratories**
- Mergers and acquisitions (M&A) activity in the sector** has been characterized by the **strategic acquisition of laboratories by other laboratories** seeking to **expand geographically and strengthen their specialization**. Likewise, the main players in the sector are acquiring laboratories in order to consolidate their position in the market

Clinical Laboratory Services Industry M&A Deal Size and Volume



Clinical Laboratory Services M&A Average EV/EBITDA and EV/Revenue



Source: Fortune Business Insights, Lighthouse Lab Services, and Capital IQ

# Clinical Laboratory Services – Global Comparable Public Companies

The table below presents selected publicly traded companies in the sector, serving as benchmarks for valuation, scale, and operating performance across comparable business models

| Company              |                                                                                      | Country | Market<br>Cap.<br>US\$M | Enterprise<br>Value<br>US\$M | Revenue<br>US\$M | EBITDA<br>Margin | Annual Average<br>EV/EBITDA |       | Second Quarter<br>Jun. 30, 2026<br>EV/<br>EBITDA |                |
|----------------------|--------------------------------------------------------------------------------------|---------|-------------------------|------------------------------|------------------|------------------|-----------------------------|-------|--------------------------------------------------|----------------|
|                      |                                                                                      |         |                         |                              |                  |                  | 2024                        | 2025  | EV/<br>EBITDA                                    | EV/<br>Revenue |
| Alliança Saúde       |    | BRA     | \$92                    | \$213                        | \$239            | 15.2%            | 20.2x                       | 8.9x  | 5.9x                                             | 0.9x           |
| Dian Diagnostics     |    | CHN     | \$1,686                 | \$2,051                      | \$1,469          | 10.5%            | 9.2x                        | 14.1x | 13.3x                                            | 1.4x           |
| Fleury               |    | BRA     | \$1,616                 | \$2,253                      | \$1,641          | 25.8%            | 6.7x                        | 5.2x  | 5.3x                                             | 1.4x           |
| Healius              |  | AUS     | \$196                   | \$811                        | \$948            | 16.9%            | 7.7x                        | 6.7x  | 5.1x                                             | 0.9x           |
| H.U. Group           |  | JPN     | \$1,122                 | \$1,284                      | \$1,521          | 10.4%            | 11.2x                       | 10.2x | 8.1x                                             | 0.8x           |
| Integral Diagnostics |  | AUS     | \$515                   | \$910                        | \$531            | 17.5%            | 10.7x                       | 15.1x | 9.8x                                             | 1.7x           |
| Krsnaa Diagnostics   |  | IND     | \$187                   | \$205                        | \$85             | 29.8%            | 16.2x                       | 14.0x | 8.1x                                             | 2.4x           |
| Terveystalo          |  | FIN     | \$1,110                 | \$1,721                      | \$1,417          | 18.1%            | 8.7x                        | 8.2x  | 6.7x                                             | 1.2x           |
| Excluded from mean   |                                                                                      |         |                         |                              |                  | Mean             | 10.1x                       | 10.3x | 7.8x                                             | 1.3x           |
|                      |                                                                                      |         |                         |                              |                  | Median           | 10.0x                       | 9.5x  | 7.4x                                             | 1.3x           |



# Clinical Laboratory Services – Global Comparable Public Companies

The table below presents selected publicly traded companies in the sector, serving as benchmarks for valuation, scale, and operating performance across comparable business models

| Company             |                                                                                      | Country | Market<br>Cap.<br>US\$M | Enterprise<br>Value<br>US\$M | Revenue<br>US\$M | EBITDA<br>Margin | Annual Average<br>EV/EBITDA |       | Second Quarter<br>Jun. 30, 2026<br>EV/<br>EBITDA |  | EV/<br>Revenue |
|---------------------|--------------------------------------------------------------------------------------|---------|-------------------------|------------------------------|------------------|------------------|-----------------------------|-------|--------------------------------------------------|--|----------------|
|                     |                                                                                      |         |                         |                              |                  |                  | 2024                        | 2025  |                                                  |  |                |
| Eurofins Scientific |    | LUX     | \$13,688                | \$17,882                     | \$8,336          | 22.2%            | 9.4x                        | 8.7x  | 9.7x                                             |  | 2.1x           |
| Labcorp             |    | USA     | \$22,960                | \$29,290                     | \$14,144         | 18.0%            | 12.3x                       | 13.2x | 11.5x                                            |  | 2.1x           |
| Medicover           |    | SWE     | \$3,606                 | \$5,139                      | \$2,770          | 15.2%            | 13.2x                       | 15.1x | 12.2x                                            |  | 1.9x           |
| Quest Diagnostics   |  | USA     | \$23,462                | \$29,856                     | \$11,278         | 24.3%            | 9.8x                        | 10.6x | 10.9x                                            |  | 2.6x           |
| RadNet              |  | USA     | \$4,849                 | \$6,601                      | \$2,144          | 17.9%            | 15.2x                       | 17.1x | 17.2x                                            |  | 3.1x           |
| Sonic Healthcare    |  | AUS     | \$7,113                 | \$10,956                     | \$7,210          | 16.7%            | 11.0x                       | 10.2x | 9.1x                                             |  | 1.5x           |
| Excluded from mean  |                                                                                      |         |                         |                              |                  | Mean             | 11.1x                       | 10.7x | 10.7x                                            |  | 2.0x           |
|                     |                                                                                      |         |                         |                              |                  | Median           | 11.7x                       | 11.9x | 11.2x                                            |  | 2.1x           |

# Clinical Laboratory Services – Global Transactions

The table below highlights selected global M&A transactions during Q2 2026, illustrating strategic acquisitions focused on scale, product diversification, or geographic expansion within the sector


| Date    | Target                                                                              | Country | Description                                                                                                                                                                                                   | Buyer                                                                                 | Seller                                                                                | %<br>Acquired | Size<br>US\$M | EV/<br>EBITDA | EV/<br>Revenue |
|---------|-------------------------------------------------------------------------------------|---------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------|---------------|---------------|---------------|----------------|
| May-26  |    | USA     | <b>CortiCare</b> , a provider of remote EEG monitoring and neurodiagnostic services, acquired <b>Integris Neuro</b> , a provider of continuous EEG monitoring services                                        |    | -                                                                                     | 100.0%        | -             | -             | -              |
| May-26* |    | AUS     | <b>Jardine Matheson Holdings</b> , a diversified holding company, agreed to acquire <b>I-MED Holdings</b> , a provider of diagnostic imaging and teleradiology services                                       |    |    | 100.0%        | \$2,440.4     | -             | -              |
| Apr-26* | <b>Global Microbiology Business of Thermo Fisher Scientific</b>                     | USA     | <b>Astorg</b> , a private equity firm, agreed to acquire <b>the Global Microbiology Business of Thermo Fisher Scientific</b> , a provider of antimicrobial susceptibility testing and culture media solutions |  |  | 100.0%        | \$1,075.0     | -             | 1.7x           |
| Apr-26  |  | USA     | <b>Function Health</b> , a provider of preventive health testing and diagnostics, acquired <b>Getlabs</b> , a provider of mobile phlebotomy and at-home lab testing services                                  |  | -                                                                                     | 100.0%        | -             | -             | -              |

*\*Announced transactions pending approval and other customary closing conditions*



# Sign up for M&A insights

We deliver sector-specific intelligence designed specifically for industry leaders, private equity firms, and their advisors. Our industry reports and featured articles deliver real-time access to key industry data, including:



Emerging  
industry trends

Quarterly reports  
covering 30+ industries

Monthly reports for the U.S.,  
Mexico, and Colombia

Transaction analysis  
and market trends

Valuable insights  
for industry leaders

**Receive email updates with our proprietary data, reports, and insights as they are published across key industries**

SUBSCRIBE



# Global M&A Representative Engagements

|                                      |                                                          |                                                                                       |                                 |                                                                                                                                                      |                                                                            |                                                                     |
|--------------------------------------|----------------------------------------------------------|---------------------------------------------------------------------------------------|---------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------|---------------------------------------------------------------------|
| <p>has been acquired by</p>          | <p>has sold a controlling interest to</p>                | <p>has sold</p> <p>Zinc Oxide Corporation</p> <p>a subsidiary of</p>                  | <p>has acquired</p> <p>from</p> | <p>has been acquired by</p>                                                                                                                          | <p>Oxbow's Senior Subordinated debt issued by</p> <p>was refinanced by</p> | <p>has acquired</p>                                                 |
| <p>has sold</p> <p>to</p>            | <p>has sold</p> <p>and</p> <p>to</p>                     | <p>has sold</p> <p>to</p>                                                             | <p>has sold</p> <p>to</p>       | <p>has sold</p> <p>Triumph Air Repair, the APU Overhaul Operations of Triumph Aviation Services – Asia, and Triumph Engines businesses</p> <p>to</p> | <p>has acquired</p>                                                        | <p>has sold its GRACE Membranes business</p> <p>a subsidiary of</p> |
| <p>has sold</p> <p>and</p> <p>to</p> | <p>has sold</p> <p>to</p> <p>Driving Safety Forward™</p> | <p>has sold</p> <p>A division of Carrier Commercial Refrigeration, Inc.</p> <p>to</p> | <p>has sold</p> <p>to</p>       | <p>has sold</p> <p>to</p>                                                                                                                            | <p>has acquired</p> <p>Wabi Development Corporation</p>                    | <p>has been recapitalized by</p>                                    |





**JAMES A. SEALE**

President and Founder | Washington, DC

  +1 (703) 623-9253

30+ years of global M&A experience, Attorney, CPA Arthur Andersen, and Professor of Global Investment Banking at George Washington University  
University of Virginia - JD  
University of Kentucky - BS in Accounting



**BRETT M. CARMEL**

Senior Managing Director and Co-founder | Miami, FL

  +1 (703) 294-6530

25+ years of global M&A experience and Professor of M&A at Johns Hopkins University  
The George Washington University - MBA International Business and MA - International Affairs  
University of Florida - BA in Political Science with High Honors



**SERGIO GARCIA DEL BOSQUE**

Managing Director | Mexico City, Mexico

  +52 (55) 8000-7463

17+ years of global M&A experience  
IPADE - MBA  
Instituto Tecnológico y de Estudios Superiores de Monterrey  
BS in Industrial Engineering



**ROBERT E. WHITNEY**

Managing Director | Washington, DC

  +1 (703) 801-8939

19+ years of global M&A experience, CPA Deloitte & Touche, Corporate Audit and Assurance Services  
University of Richmond - BS Business Administration in Accounting



**CARLOS HERNANDEZ GOUDET**

Managing Director | San Luis Potosi, Mexico

  +1 (571) 482-3432

16+ years of global M&A experience  
Columbia Business School - MBA  
Instituto Tecnológico y de Estudios Superiores de Monterrey  
BS in Industrial Engineering



**FELIPE BUENO**


Senior Director | Monterrey, Mexico

  +52 (84) 4432-4444


40+ years with Grupo Industrial Saltillo with experience as Director, Corp. Dev. and extensive global commercial experience  
Instituto Tecnológico y de Estudios Superiores de Monterrey  
MBA and BS in Industrial Engineering



Washington D.C.




Miami



Mexico City



Monterrey



San Luis Potosi



For over 25 years, Seale & Associates has served leading public and private companies from around the world and operating in a broad range of industries with a high level of quality, integrity and independence while presenting innovative ideas and trusted solutions to address their most complex dealings

+25

Years of Experience

+\$50B

Closed Transactions Globally

Services & Solutions

- Mergers & Acquisitions

Divestitures

Joint Ventures / Alliances

Recapitalizations
- Due Diligence / Support

Expert Witness Testimony

Corporate Finance Advisory

Strategy Consulting

Trusted Advisor to Leading Companies Worldwide

We have worked repeatedly with many of the most well-known and respected companies in the world...

...as well as with many private equity funds, family-offices and privately held companies.







# Seale & Associates

Creative Solutions. Trusted Advice.